Therapy Areas: Oncology
Hologic receives FDA approval for Aptima HPV assay as primary screening option
4 February 2026 - Women's health company Hologic Inc (Nasdaq:HOLX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved its Aptima HPV Assay for clinician-collected ...
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
4 February 2026 - Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Can...
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
4 February 2026 - Biosion Inc, a China-based clinical-stage biotechnology company developing innovative antibody-based therapeutics, announced on Tuesday that the first patient has been dosed in a Pha...
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
3 February 2026 - US-based clinical-stage precision medicine company Relay Therapeutics, Inc. (NASDAQ: RLAY) on Tuesday said the US Food and Drug Administration has granted Breakthrough Therapy design...
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
3 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Tuesday that ...
Natera submits Signatera CDx PMA to FDA for bladder cancer use
2 February 2026 - Cell-free DNA testing company Natera Inc (NASDAQ: NTRA) said on Monday that it has submitted a premarket approval application to the US Food and Drug Administration (FDA) for Signate...